|
|
Article: Other News To Note.
- Article from:
- BIOWORLD Today
- Article date:
- November 3, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
o Akesis Pharmaceuticals Inc., of San Diego, filed a preliminary investigational new drug application with the FDA for its lead product candidate AKP-020. Once the firm has an IND approved by the FDA, the company intends to start a Phase Ib/IIa trial to assess the safety and efficacy, and determine the pharmacokinetics of AKP-020 in patients with Type II diabetes. AKP-020 is the product designation for a novel vanadium compound otherwise known as bis(ethylmaltolato)oxovanadium (IV), or BEOV.
o AlphaVax Inc., of Research Triangle Park, N.C., received a three-year, $3.6 million award from the National Institute of Allergy and Infectious Diseases. The award will ...